MarginsXMarginsX
Home › Markets › Health Care › TAK

Takeda Pharmaceutical Company Limited (TAK)

TAK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$21.59
+0.75% on the day
Market cap
$68.2B
Large cap
Revenue · 2025
$28.2B
-1.7% on 2024
Net income · 2025
-$952.4M
-3.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/0001395064-26-000177-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31. Converted from JPY at 159.9982 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerTAK on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryJapan
IPO year2018
SEC CIK0001395064
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$28.2B
Net income-$952.4M
Operating income$38.9M
Net margin-3.4%
Operating margin0.1%
Revenue growth-1.7%
Cash$3.7B
Total assets$96.9B
P/E (computed)Net income was not positive
P/S (computed)2.4×

Reported in JPY; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
595.1B JPY cash at March 31, 2026
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed June 17, 2026
Insider net buying, 12 months
-$13.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-06-17
Cash and burn595.1B JPY cash; operating cash flow 260.4B JPY a quarter.Report 2026-03-31
Shares outstanding3,159,673,660 (2026-03-31). the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures.Cover page 2026-03-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG AZSA LLC, Tokyo, JapanPCAOB Form AP 2026-07-22
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $13.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
4.51T JPY-152.4B JPY1.04T JPY595.1B JPY4.88T JPY4.51T JPY20-F 2026-06-17
FY 2025
2025-03-31
4.58T JPY107.9B JPY1.06T JPY385.1B JPY4.52T JPY4.58T JPY20-F 2025-06-25
FY 2024
2024-03-31
4.26T JPY144.1B JPY716.3B JPY457.8B JPY4.84T JPY4.26T JPY20-F 2025-06-25
FY 2023
2023-03-31
4.03T JPY317.0B JPY977.2B JPY533.5B JPY4.38T JPY4.03T JPY20-F 2025-06-25
FY 2022
2022-03-31
3.57T JPY230.1B JPY1.12T JPY849.7B JPY4.35T JPY3.57T JPY20-F 2024-06-26
FY 2021
2021-03-31
3.20T JPY376.0B JPY1.01T JPY966.2B JPY4.64T JPY3.20T JPY20-F 2023-06-28
FY 2020
2020-03-31
3.29T JPY44.2B JPY669.8B JPY637.6B JPY5.09T JPY3.29T JPY20-F 2022-06-29
FY 2019
2019-03-31
2.10T JPY135.2B JPY328.5B JPY702.1B JPY5.75T JPY2.10T JPY20-F 2021-06-29

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in JPY.

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22025-06-27
Latest annual report20-F2026-06-17
Latest quarterly / interim6-K2026-10-29

Source: SEC EDGAR submissions feed, 710 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month+15.7%
3 months+23.2%
Year to date+37.5%
1 year+50.5%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TEVATeva Pharmaceutical Industries Limited$42.57-4.34%$49.7B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
ONCBeOne Medicines Ltd.$411.29-1.26%$47.0B
GSKGSK plc$50.41-0.08%$102.0B
SNYSanofi ADS$48.39+0.04%$118.0B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
ZTSZoetis Inc.$84.39+0.68%$34.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier